60 Results for "

TAM

" in MedChemExpress (MCE) Product Catalog:
Products (60)

60 Results for "TAM" in MCE Product Catalog:

271
271 Publications Verification
Cat. No.: HY-10227
CAS No.: 179324-69-7
Purity:  99.91%
Synonyms: PS-341; LDP-341; NSC 681239
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
loading...
    loading...
217
217 Cited Publications
Cat. No.: HY-50895
CAS No.: 184475-35-2
Synonyms: ZD1839
Target:  

EGFR Autophagy Apoptosis

Research Areas:  

Cancer

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
loading...
    loading...
66
66 Cited Publications
Cat. No.: HY-15150
CAS No.: 1037624-75-1
Purity:  99.92%
Synonyms: R428; BGB324
Target:  

TAM Receptor

Research Areas:  

Cancer

Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-12494
CAS No.: 1361030-48-9
Purity:  99.64%
Target:  

TAM Receptor FLT3

Research Areas:  

Neurological Disease Cancer

LDC1267 is a AXL/TAM/FLT3 inhibitor with IC50 values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-117548
CAS No.: 1350549-36-8
Purity:  98.92%
UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18719E
CAS No.: 110025-28-0
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119039
CAS No.: 1110873-99-8
Purity:  99.75%
Target:  

TAM Receptor

Research Areas:  

Inflammation/Immunology Cancer

RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N3415
CAS No.: 3301-49-3
Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a Kd value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5 to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18719B
CAS No.: 1197194-41-4
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .
loading...
    loading...
Cat. No.: HY-116838
CAS No.: 2030241-59-7
Purity:  99.84%
Target:  

Bacterial

Research Areas:  

Infection

TAM-16 is a potent and orally active polyketide synthase 13 (Pks13) inhibitor with an IC50 value of 0.32 μM. TAM-16 has promising activity against Mycobacterium tuberculosis. TAM-16 inhibits hERG cardiac ion channel .
loading...
    loading...
Cat. No.: HY-148127
CAS No.: 1802499-21-3
Purity:  99.29%
Research Areas:  

Cancer

TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
loading...
    loading...
Cat. No.: HY-10227R
CAS No.: 179324-69-7
Synonyms: PS-341 (Standard); LDP-341 (Standard); NSC 681239 (Standard)
Bortezomib (Standard) is the analytical standard of Bortezomib. This product is intended for research and analytical applications. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
loading...
    loading...
Cat. No.: HY-173268
CAS No.: 3051784-94-9
Target:  

TAM Receptor

Research Areas:  

Cardiovascular Disease Cancer

UNC9426 is a potent and selective TYRO3 inhibitor (IC50 = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-P11108
CAS No.: 1895883-60-9
RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research .
loading...
    loading...
Cat. No.: HY-P10449
CAS No.: 3098205-40-1
Target:  

Peptides

Research Areas:  

Inflammation/Immunology Cancer

M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .
loading...
    loading...
Cat. No.: HY-147218
CAS No.: 2412356-57-9
Purity:  97.13%
Synonyms: ARRY-067
Target:  

TAM Receptor

Research Areas:  

Cancer

PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 + T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .
loading...
    loading...
Cat. No.: HY-124066
CAS No.: 1182129-77-6
Purity:  98.72%
Target:  

TAM Receptor

Research Areas:  

Cancer

RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC50in cell assays, and suppresses lung cancer tumor growth .
loading...
    loading...
Cat. No.: HY-P99746
CAS No.: 2058047-65-5
Synonyms: 3C23K; GM102

Target:  

TGF-β Receptor

Research Areas:  

Inflammation/Immunology Cancer

Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .
loading...
    loading...
Cat. No.: HY-10227S
Purity:  ≥98.0%
Synonyms: PS-341-d8; LDP-341-d8; NSC 681239-d8
Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM) . Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) .
loading...
    loading...
Cat. No.: HY-148128
CAS No.: 1802498-63-0
Purity:  98.53%
Research Areas:  

Cancer

TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .
loading...
    loading...